Back to results
US 10,434,169 B2Granted
Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus
AssigneesSillajen, Inc., Sillajen Biotherapeutics, Inc.
InventorsDavid Kirn, John Bell, Caroline Breitbach, Anne Moon, Tae-Ho Hwang, Yu Kyoung Lee, Mi-kyung Kim
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods and compositions for use in inducing tumor-specific antibody mediated complement-dependent cytotoxic response in an animal having a tumor comprising administering to said animal a composition comprising a replication competent oncolytic virus wherein administration of the composition induces in the animal production of antibodies that mediate a CDC response specific to said tumor.
Claims13
A method of identifying a tumor-specific antigen comprising
- a) contacting (i) a plurality of expression vectors into which a cDNA library prepared from a cancer cell has been cloned with (ii) serum isolated from one or more human subjects having a tumor, said one or more subjects having been administered a replication competent oncolytic Wyeth or Western Reserve strain vaccinia virus in an amount effective to mediate a complement dependent cytotoxic (CDC) response specific to said tumor in the subject prior to isolating said serum;
- and
- b) isolating antigens from said cDNA library that are recognized by the serum, wherein the method further comprises confirming the presence of CDC response-producing antibodies in said serum after the replication competent oncolytic virus has been administered and before contacting said serum with said plurality of expression vectors.
Dependencies are inferred from the claim text.